SS Innovations International Inc. (NASDAQ: SSII) is staking out a position in telerobotic surgery as remote procedures gain momentum worldwide, according to a recent MedTech Dive report. The company's founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, told the publication that robotic surgery is inherently a form of teleoperation, and the critical technical challenge is determining how much distance can be introduced without compromising responsiveness. That question is central to the broader adoption of telesurgery, which allows surgeons to operate on patients located far away using robotic systems.
For investors, the development matters because telerobotic surgery could significantly expand the addressable market for surgical robotics, particularly in regions with limited access to specialized surgeons. SS Innovations has reported 195 robotic telesurgeries using its SSi Mantra system as of September 28, 2026, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems as of the same date, up 45% from the end of 2025, while cumulative procedures totaled 14,503. Those figures suggest growing clinical adoption and real-world experience, which are critical for regulatory approvals and physician confidence.
The SSi Mantra system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. These international deployments demonstrate the system's versatility and its ability to support advanced procedures across different geographies. SS Innovations is currently pursuing U.S. FDA clearance and European Union CE marking as it seeks to expand into additional international markets. Securing those approvals would open the door to the world's largest healthcare markets and could accelerate revenue growth.
The MedTech Dive article, “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery. It highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers. For those tracking the sector, the full article is available at https://ibn.fm/4ZLvL. More details on SS Innovations' telerobotic surgery progress can be found at Read More>>. The company's newsroom is maintained at https://ibn.fm/SSII, and its investor relations profile is available at SS Innovations International (NASDAQ: SSII).
MissionIR, a specialized communications platform, distributes content to enhance visibility for companies like SS Innovations. It operates within a broader network; for instance, MissionIR is one of more than 75 brands in the Dynamic Brand Portfolio at IBN. That network provides wire distribution through InvestorWire, among other services. These channels help ensure that developments in telerobotic surgery reach a wide audience of investors and industry observers.
The implications of SS Innovations' progress extend beyond the company itself. As telesurgery gains ground, it could reshape how surgical care is delivered, particularly in underserved areas. Regulatory clearances in the U.S. and Europe would not only validate the technology but also set a precedent for remote surgical practices. With 195 telesurgeries already performed and a rapidly growing installed base, SS Innovations appears well positioned to capitalize on this trend, provided it can navigate the complex regulatory landscape and demonstrate consistent clinical outcomes.
